Cervical Cancer Screening in Average-Risk Women: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians
View abstract on PubMed
Summary
This summary is machine-generated.Average-risk women should begin cervical cancer screening at age 21 with cytology every 3 years. Screening can shift to co-testing cytology and HPV tests every 5 years at age 30, or stop after 65 with negative results.
Area Of Science
- Gynecology
- Oncology
- Preventive Medicine
Background
- Cervical cancer screening guidelines aim to detect precancerous changes and cancer early.
- Current recommendations are based on evidence from systematic reviews and clinical studies.
- Adherence to screening protocols is crucial for effective cervical cancer prevention.
Purpose Of The Study
- To outline the indications for cervical cancer screening in asymptomatic, average-risk women.
- To provide evidence-based best practice advice for clinicians regarding screening protocols.
- To define age-specific recommendations for initiating, frequency, and cessation of screening.
Main Methods
- Review of relevant publications, including systematic reviews, supporting current cervical cancer screening guidelines.
- Distillation of evidence to formulate best practice recommendations for average-risk women.
- Focus on cytologic testing and human papillomavirus (HPV) testing protocols.
Main Results
- Screening should commence at age 21 with cytology every 3 years for average-risk women.
- HPV testing is not recommended for women younger than 30.
- Co-testing with cytology and HPV every 5 years is an option for women aged 30+.
- Screening cessation is advised for women over 65 with a history of negative tests.
- Women who have had a hysterectomy with cervix removal should not be screened.
Conclusions
- Age, screening history, and testing modality are key factors in cervical cancer screening decisions.
- Tailored screening schedules, including cytology and HPV testing, optimize early detection and prevention.
- Discontinuation of screening in specific populations, such as post-hysterectomy or older women with negative results, is recommended.